Project Grant R01DK142742
- Federal Project Grant Award Summary Duke University received a $3.19 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on August 21, 2025, with a completion date of July 31, 2029. The research focuses on addressing critical immunological challenges associated with recombinant adeno-associated virus (AAV) gene therapy delivery. AAV vectors have emerged as promising...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $686,129 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on January 16, 2026, with a completion date of November 30, 2029. The award supports research on intraductal gene therapy for liver cirrhosis, addressing a critical gap in hepatic gene delivery by...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $786,216 Project Grant to the University of California, Los Angeles (UCLA) on August 28, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This four-year research initiative, concluding June 30, 2029, supports fundamental biomedical research investigating the post-transcriptional regulation of hepatokines and their role in systemic...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $806,192 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded July 1, 2025, with completion targeted for April 30, 2030. The award funds research investigating the roles of MRP9 (multidrug resistance-associated protein 9), encoded by the ABCC12 gene, in...
- Federal Grant Award Summary Aavogen Inc. received a $350,000 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 5, 2025 through September 4, 2026. The award supports preclinical validation of AVGN7 (rAAV6:SMAD7), a gene therapeutic designed to treat obesity and type 2 diabetes mellitus (T2DM) by enhancing skeletal muscle mass and...
- Federal Grant Award Summary The University of Pennsylvania received a $665,725 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective February 1, 2026, with completion expected by December 31, 2029. The award funds molecular genetic research to advance understanding of cellular senescence in liver disease, with particular focus on identifying...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Johns Hopkins University a $1.21 million Project Grant (CFDA 93.847: Diabetes, Digestive, and Kidney Diseases Extramural Research) to conduct basic research on the role of phospholipase A2 group XIIB (PLA2G12B) in apolipoprotein B-containing lipoprotein assembly, plasma lipid metabolism, and cardiovascular disease risk. The research investigates how PLA2G12B facilitates triglyceride...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded the University of California Santa Cruz a $572,623 Project Grant effective September 1, 2025, through August 31, 2028, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). This research initiative investigates the interplay between early-life enteric virus infection and the development of oral tolerance in the gastrointestinal tract, with...
- Federal Grant Award Summary The Children's Hospital of Philadelphia Research Institute received an $888,836 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with completion targeted for May 31, 2029. The research project focuses on developing novel therapeutic approaches for Hemophilia A, an X-linked bleeding disorder caused by Factor VIII (FVIII) deficiency. The initiative aims to...
- Federal Project Grant Award Summary Oregon Health & Science University (OHSU) received a $1,329,538 Project Grant awarded on July 1, 2025, from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research project, titled "Allogeneic Hepatocyte Transplantation Without Immunosuppression," will be conducted through April 30, 2030, at OHSU's Portland, Oregon...
The University of North Carolina at Chapel Hill received a $763,647 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on adeno-associated virus (AAV) liver interactions and genetic factors affecting AAV gene therapy outcomes. The project, which commenced February 15, 2026 and extends through December 31, 2029, will deliver research findings on the genetic determinants underlying interpatient variability in AAV hepatotoxicity and transgene expression efficiency using Collaborative Cross mice—a genetically diverse reference population designed to identify candidate genes associated with drug susceptibility and adverse outcomes. The research will produce scientific outputs across three primary aims: characterization of genetic associations between host background and biomarkers predictive of liver toxicity and transgene expression stability; identification of non-genetic factors influencing AAV transduction; and validation of in vivo findings using cultured hepatocyte spheroids prepared from selected mouse strains. These deliverables are intended to generate novel insights that improve the safety and efficacy profiles of AAV-based gene therapies, addressing a critical need in this therapeutic domain given the FDA approval of six AAV vector-based biodrugs and the associated liver toxicity challenges that have limited clinical outcomes in liver-directed therapies.Summary: Genetic Determinants of AAV Liver Transduction and Toxicity
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $763.6k | 2/9/26 |